Niaprazin

Niaprazin, fenilpiperazin grubunun yatıştırıcı-hipnotik bir ilacıdır.[1][2] 1970'lerin başından beri Fransa, İtalya ve Lüksemburg dahil olmak üzere birçok Avrupa ülkesinde uyku bozukluklarının tedavisinde kullanılmaktadır.[3][4] Uygun güvenlik ve tolere edilebilirlik profili ve kötüye kullanım potansiyeli olmaması nedeniyle çocuklar ve ergenlerde yaygın olarak kullanılır.[5][6][7][8][9][10]

Kaynakça

[değiştir | kaynağı değiştir]
  1. ^ The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. Springer. 14 Kasım 2014. ss. 862-. ISBN 978-1-4757-2085-3. 
  2. ^ Sleep: physiology, investigations, and medicine. New York: Kluwer Academic/Plenum. 2003. ISBN 978-0-306-47406-4. 
  3. ^ Swiss Pharmaceutical Society (2000). Index Nominum 2000: International Drug Directory (Book with CD-ROM). Boca Raton: Medpharm Scientific Publishers. ISBN 978-3-88763-075-1. 
  4. ^ Dictionary of Pharmacological Agents. Boca Raton: Chapman & Hall/CRC. 1996. ISBN 978-0-412-46630-4. 
  5. ^ "[Niaprazine in behavior disorders in children. Double-blind comparison with placebo]". La Pediatria Medica e Chirurgica: Medical and Surgical Pediatrics (İtalyanca). 9 (2): 185-7. 1987. PMID 2958783. 
  6. ^ "[Niaprazine and side effects in pediatrics. Cooperative evaluation of French centers of pharmacovigilance]". Thérapie (Fransızca). 43 (4): 307-11. 1988. PMID 2903572. 
  7. ^ "The effect of niaprazine on some common sleep disorders in children. A double-blind clinical trial by means of continuous home-videorecorded sleep". Child's Nervous System. 7 (6): 332-5. October 1991. doi:10.1007/bf00304832. PMID 1837245. 
  8. ^ "Niaprazine vs chlordesmethyldiazepam in sleep disturbances in pediatric outpatients". Pharmacological Research. 25 Suppl 1: 83-4. 1992. doi:10.1016/1043-6618(92)90551-l. PMID 1354861. 
  9. ^ "Insomnia in children: when are hypnotics indicated?". Paediatric Drugs. 4 (6): 391-403. 2002. doi:10.2165/00128072-200204060-00006. PMID 12038875. 
  10. ^ "Anxiolytics, hypnotics, and antidepressants dispensed to adolescents in a French region in 2002". Pharmacoepidemiology and Drug Safety. 15 (7): 494-503. July 2006. doi:10.1002/pds.1258. PMID 16700077.